NCT04872543 - A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 29, 2021

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions

Malignant Peripheral Nerve Sheath Tumors (MPNST)

Interventions

DRUG

ASTX727

ASTX727 will be self-administered orally by the patient on a once daily basis, days 1 through 5 of each 21-day cycle. Cycle 1 day 1 (C1D1) is defined as the first day that ASTX727 is administered.

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors

collaborator

Taiho Pharmaceuticals, Inc.

UNKNOWN

lead

Memorial Sloan Kettering Cancer Center

OTHER